Clinical Trial Update: A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating JNJ-42160443 as add-on treatment for low back pain, including recurrent cases; the trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low Back Pain
• Low Back Pain Recurrent

Drugs mentioned

• JNJ-42160443

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Low Back Pain, Low Back Pain, Recurrent | Phase 2 | Status: TERMINATED